Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Eidos Therapeutics

Eidos Therapeutics
2013 FOUNDED
PUBLIC STATUS
21-30 EMPLOYEES
EIDX STOCK SYMBOL
$27.26 SHARE PRICE (As of Thursday Closing)
Description

Eidos Therapeutics Inc is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. TTR is a protein that occurs naturally in the form of a tetramer and performs multiple beneficial roles, including the transport of essential hormones and vitamins. The company's product candidate, AG10, is an orally-administered small molecule designed to potently stabilize tetrameric TTR.

Website
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
NAS
Primary Office
  • 101 Montgomery Street
  • Suite 2550
  • San Francisco, CA 94101
  • United States

+1 (415) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Eidos Therapeutics’s full profile, request a free trial.

Eidos Therapeutics Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$8.89 - $29.74 $1B $27.49 -$1.57 152K 36.8M

Eidos Therapeutics Financials Summary

In Thousands,
USD
TTM
31-Mar-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 695,153 517,172
Revenue 0 0 0 0
EBITDA (36,818) (40,669) (11,937) (2,542)
Net Income (36,879) (40,725) (11,941) (2,542)
Total Assets 153,197 160,112 6,343 1,975
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Eidos Therapeutics Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Eidos Therapeutics‘s full profile, request access.

Request full access to PitchBook

Eidos Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore Eidos Therapeutics‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

Eidos Therapeutics Competitors (42)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aquinox Pharmaceuticals Formerly VC-backed Vancouver, Canada 0 00000 00000000000 00000
0000000 0000000000 Corporation San Diego, CA 00 00000 000000000 00000
00 000000000000000 Formerly VC-backed Cambridge, MA 00 00000 00000000000 00000
000 00000000000 00 Venture Capital-Backed Burnaby, Canada 00 000.00 0000000000 0 000.00
00000 Formerly VC-backed Cambridge, MA 000 00000 0&0
To view this company’s complete list of competitors, request access »

Eidos Therapeutics Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Eidos Therapeutics‘s full profile, request access.

Request full access to PitchBook

Eidos Therapeutics Executive Team (7)

Name Title Board
Seat
Contact
Info
Jonathan Fox MD President & Chief Medical Officer
Christine Siu Chief Financial Officer
Uma Sinha Ph.D Chief Scientific Officer
Camille Landis Chief Business Officer
Isabella Graef MD Co-Founder & Board Observer
You’re viewing 5 of 7 executives. Get the full list »

Eidos Therapeutics Board Members (5)

Name Representing Role Since Contact
Info
Hoyoung Huh Ph.D Self Board Member 000 0000
Isabella Graef MD Eidos Therapeutics Co-Founder & Board Observer 000 0000
Neil Kumar Ph.D Self Chief Executive Officer & Board Member 000 0000

2 Former Board Members

You’re viewing 3 of 5 board members. Get the full list »